Jul 14, 2025, 00:06

Novartis Oncology Professional Medical Education Grants

Novartis Oncology’s Office of Grants and Education (OGE) funds independent, nonpromotional medical education programs to deliver up-to-date scientific information to health care professionals and improve patient care across a range of oncology indications.

Eligibility Criteria:

Accredited continuing medical education providers
Hospitals, community health centres, academic medical centres, medical universities
Professional medical associations/societies, managed care organizations, medical education companies/providers
Activities must comply with all applicable legal, regulatory, and ethical standards; funding requests linked to prescribing or purchasing decisions are prohibited

Funding Details:

Support for fellowships, research or merit awards, non-CME closed research meetings, health policy requests, and society membership dues
Funds may cover program development costs, educational needs assessments, learning-objective and agenda planning, outcomes measurement, and detailed line-item budgets (no meals-only or lavish venue requests)
Therapeutic areas include AML, breast cancer, CML, endocrine diseases (acromegaly, Cushing’s), ITP, MDS, melanoma, multiple myeloma, NSCLC, neuroendocrine tumours, RCC, severe aplastic anaemia, T-cell therapies, and tuberous sclerosis complex

Deadline:

Submit at least 60 days before your program’s start date. Late requests (under 60 days) or activities already underway will not be considered.

Where to Go for Further Information:

All applications must be submitted online via Novartis Grants Central Station (NGCS):

For US-based or US-participant activities, submit under “Professional Medical Education” request type.

For non-US activities without US participants, email: [email protected]

cancer CME grants fellowship grants health-care professional education Hematology medical education Melanoma Novartis OncoDaily Oncology solid tumours

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding